BioNTech's Cancer Drug Data Fuels Optimism for 2026 Regulatory Filing

BioNTech's BNT323 shows 47.9% response in endometrial cancer trial, outperforming chemo. Plans 2026 FDA filing. Stock rose 7.6% on the news.

A new cancer therapy candidate from BioNTech has demonstrated a significant clinical advantage over standard chemotherapy, providing tangible evidence for the company's strategic pivot toward oncology. In a Phase 2 trial involving patients with advanced endometrial cancer, the antibody-drug conjugate trastuzumab pamirtecan (BNT323) achieved a confirmed objective response rate of 47.9%. This compares to a response rate of roughly 15% with conventional chemotherapy. The company and its partner DualityBio plan to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration in 2026.

The data, which sent BioNTech's shares up 7.59% on a weekly basis to €83.65, are particularly notable for their performance in hard-to-treat patients. The trial cohort included 145 patients, some with lower HER2 expression levels where many therapies fail. The median progression-free survival was 8.1 months, compared to approximately four months with chemotherapy. For patients who had previously received checkpoint inhibitors, the response rate climbed to 49.3%.

This performance profile sets BNT323 apart from a key competitor, AstraZeneca and Daiichi Sankyo's Enhertu, which received accelerated FDA approval in April 2024 but is limited to tumors with high HER2 expression. BioNTech's candidate shows strong activity across expression levels, potentially opening treatment to a new patient group. The drug already holds Fast Track and Breakthrough Therapy designations from the FDA, which can accelerate the regulatory pathway. A global Phase 3 confirmatory trial, Fern-EC-01, is currently underway.

Wall Street analysts issued a flurry of notes in response, revealing a split in sentiment. Morgan Stanley confirmed its "Overweight" rating and raised its price target to $126. Berenberg Bank reiterated its buy recommendation. Bank of America Securities lifted its target to $130, viewing a potential approval as a cornerstone for building BioNTech's own oncology commercial infrastructure. However, Leerink Partners cut its target sharply from $113 to $94, maintaining a "Market Perform" rating due to perceived lower success odds for another lung cancer candidate.

The consensus among analysts remains bullish. The average price target from 18 covering the stock stands at $133, well above the current share price of €84.15. Of 19 experts, 15 currently recommend buying the shares. Despite recent gains, the stock trades about 20% below its 52-week high of €105.90, though it has recovered significantly from a March low of €72.50. It continues to trade below the technically significant 200-day moving average at €88.09.

Financing this expensive strategic transition is a central challenge. BioNTech expects revenue to decline by about 25% in 2026 to a range of €2.0 to €2.3 billion, following a net loss of €1.14 billion the prior year. The company does not anticipate commercial revenue from its new oncology assets before 2027. Its substantial war chest provides crucial runway, with a liquidity reserve of approximately €17.2 billion at the end of 2025. This capital is needed to fund 15 ongoing Phase 3 trials through the end of 2026 and deliver data packages from seven late-stage programs, with R&D expenses for 2026 alone projected to reach up to €2.5 billion.

Investors face several near-term milestones. The company will report its first-quarter 2026 results on May 5, offering an early financial snapshot of its oncology narrative. Ten days later, on May 15, BioNTech will hold its virtual Annual General Meeting. Shareholders will vote on key governance changes, including expanding the supervisory board from six to eight members to bring in more expertise for clinical development and oncology commercialization, and authorizing new capital of up to €129.5 million.